Leila JaafarFounder

Switzerland - Basel, Basel

With over 15 years of experience in the field of biophysics and radiopharmaceuticals, I am passionate about developing and delivering innovative solutions for cancer patients. I am the CEO and Founder of NUCLIDIUM AG, a pharmaceutical company focusing on the development of copper-based radioligand therapeutics and companion diagnostics aimed at addressing various solid tumor conditions such as prostate cancer, breast cancer, and neuroendocrine tumors. I am also the Co-Founder of LinaThera GmbH, a company that develops accelerator facilities for producing radionuclides and offers contract manufacturing of radiopharmaceuticals. My mission is to make these transformative treatments accessible through secure supply chains and to create value for patients, partners, and investors.

At NUCLIDIUM AG, I lead a team of experts in the fields of chemistry, biology, physics, engineering, and clinical development and oversee the strategic vision, operations, and partnerships of the company. I have successfully secured multiple rounds of funding, secured large international research grants, and established collaborations with leading research institutes and hospitals towards regulatory approvals for our products. I leverage my skills in co-creation, start-up leadership, and computational engineering to drive innovation, optimize processes, and solve complex challenges. I am proud of the impact that our company has made in advancing the field of radioligand therapeutics and improving the lives of cancer patients.